Zobrazeno 1 - 10
of 20
pro vyhledávání: '"John A. Hohneker"'
Autor:
Jeremey Levin, John A. Hohneker
Publikováno v:
Investigational New Drugs. 18:383-390
Eniluracil (776C85, GW776) inactivates dihydropyrimidine dehydrogenase (DPD), the principal enzyme of 5-fluorouracil (5-FU) catabolism. Inactivation of DPD eliminates a potential mechanism for tumor 5-FU resistance and permits achievement of reliable
Autor:
K. A. Havlin, John A. Hohneker, Christine M. Legler, Eric P. Winer, Ursula A. Matulonis, Daniel F. Hayes, Michael J. Ramirez, Lydsay N. Harris
Publikováno v:
Cancer Chemotherapy and Pharmacology. 43:68-72
Vinorelbine (Navelbine) is a semi-synthetic vinca alkaloid with documented activity in breast cancer. The major dose-limiting toxicity (DLT) when given weekly is myelosuppression with minimal neurologic toxicity. This phase I study attempted to defin
Autor:
Suzanne F. Jones, Dieras, Smith L, John A. Hohneker, Eckardt, H. A. Burris, G. I. Rodriguez, Bigley J, Peacock Nw, Hardy J, Von Hoff Dd
Publikováno v:
Investigational New Drugs. 16:37-43
Vinorelbine (Navelbine®) is a unique semi-synthetic vinca-alkaloid with a favorable safety profile that has demonstrated significant antitumor activity in patients with non-small cell lung cancer, advanced breast cancer, advanced ovarian cancer and
Autor:
Eric K. Rowinsky, Marna Doucette, Ross C. Donehower, Sharyn D. Baker, Louise B. Grochow, Alex A. Adjei, Tom Spector, Dennis A. Noe, John A. Hohneker, Soo Peang Khor, S E Sartorius
Publikováno v:
Journal of Clinical Oncology. 14:3085-3096
PURPOSE To study the absolute bioavailability and pharmacokinetics of an oral solution of fluorouracil (5-FU) in patients treated with 776C85, an oral inactivator of dihydropyrimidine dehydrogenase (DPD), and to evaluate the feasibility of administer
Autor:
Barbara L. Weber, John A. Hohneker, Stephen E. Jones, Joseph Bigley, Charles L. Vogel, Harold A. Harvey, Laura F. Hutchins
Publikováno v:
Journal of Clinical Oncology. 13:2722-2730
PURPOSE We evaluated single-agent intravenous (IV) vinorelbine as first- and second-line treatment for advanced breast cancer (ABC) in patients who were not resistant to anthracyclines. Objective tumor response (TR) and toxicity were assessed. PATIEN
Autor:
Stephen H, Rosenoff, Nashat Y, Gabrail, Richard, Conklin, John A, Hohneker, William J, Berg, Ghulam, Warsi, Jennifer, Maloney, John J, Benedetto, Elizabeth A, Miles, Wei, Zhu, Lowell, Anthony
Publikováno v:
The journal of supportive oncology. 4(6)
Diarrhea is a well-recognized side effect of chemotherapy and can result in chemotherapy delay and/or dose reduction, potentially reducing the therapeutic benefit of treatment. Octreotide has been shown to be effective in controlling chemotherapy-ind
Autor:
John A, Hohneker, Alan L, Bess
Publikováno v:
Texas dental journal. 122(9)
Autor:
Al B. Benson, Paul S. Ritch, J. P. Burnham, T. Bonny, J. Levin, B. Klencke, C. McGuirt, Edith P. Mitchell, John A. Hohneker, N. Abramson
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 13(4)
Background: Conventional systemic chemotherapy currently available for patients with inoperable hepatocellular carcinoma is ineffective. The purpose of this study was to evaluate the safety and efficacy of eniluracil/5-fluorouracil (5-FU) in the trea
Autor:
Howard Hochster, Jacob Lokich, Charles H. Weaver, William N. Bell, John A. Hohneker, Mark A. O’Rourke, Eric M. Chevlen, Chip McGuirt, Richard L. Schilsky, Sridhar Mani, Robin L. White, Thomas L. Beck, Jeremey Levin
Publikováno v:
Scopus-Elsevier
Europe PubMed Central
Europe PubMed Central
PURPOSE: To determine the efficacy of fluorouracil (5-FU) plus eniluracil when administered to patients with previously untreated metastatic colorectal cancer. PATIENTS AND METHODS: In this single-arm phase II study, patients with previously untreate
Autor:
Al Guaspari, J. Taylor Wharton, Mitchell Morris, Robert C. Bast, David M. Gershenson, John A. Hohneker, Thomas W. Burke
Publikováno v:
Gynecologic oncology. 70(3)
To determine the toxicity and activity of intravenous vinorelbine given daily for 3 consecutive days every 3 weeks in patients with platinum-resistant epithelial ovarian cancer.Between September 1994 and October 1995, 23 women with refractory epithel